BioAtlantis

BioAtlantis is a biotechnology company that provides sustainable technologies to enhance plant, animal and human health.
With science and technology at its centre, BioAtlantis leads the scientific-based movement to reduce the world’s dependence on agrochemicals and avoid the overuse of antibiotics in animals which is causing a build-up of resistance to antibiotics important to humans.
A hugely efficient and automated seaweed extraction facility in Tralee built by BioAtlantis is the largest in Britain or Ireland and can concurrently produce amino and humic acids.
BioAtlantis is on the threshold of major expansion following 16 years of continued, specifically targeted investment in science and engineering while simultaneously collaborating with leading academic institutions, working on solving specific problems in plant, animal and human health.
In the 1990s, BioAtlantis CEO, John T. O’Sullivan, identified nutraceuticals as a future growth industry to prevent health problems without the use of synthetic compounds. He pioneered the extraction of bioactives from seaweed, founding BioAtlantis in 2004. He used his experience and understanding of the dairy industry, transferring the best practices and innovative techniques from there, to seaweed extraction.
From the beginning, BioAtlantis forged strong, lasting links with academia which is now backed up by 84 peer reviewed papers in collaboration with distinguished third level institutions around the world.
Applying a ‘fitness-for-purpose’ approach to product development and validation was successfully employed to produce naturally derived products, based on bioactive compounds of known function, mode-of-action, stability and safety. These compounds are proven to have an efficacy equivalent to or greater than synthetics.